Who are Vincristine and Topotecan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vincristine-and-topotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Vincristine and Topotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vincristine and Topotecan (Vincristine and Topotecan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca alkaloid and topoisomerase I inhibitor. Area: Oncology.

phase 3 Vinca alkaloid and topoisomerase I inhibitor Microtubules and topoisomerase I Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Vincristine and Topotecan (Vincristine and Topotecan) — St. Jude Children's Research Hospital. Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vincristine and Topotecan TARGET	Vincristine and Topotecan	St. Jude Children's Research Hospital	phase 3	Vinca alkaloid and topoisomerase I inhibitor	Microtubules and topoisomerase I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vinca alkaloid and topoisomerase I inhibitor class)

St. Jude Children's Research Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vincristine and Topotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/vincristine-and-topotecan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab